Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo

Prostate

Volumn 62, Issue 3, 2005, Pages 282-289

  Palmer, Jodie ^a,b   Ernst, Matthias ^c   Hammacher, Annet ^d   Hertzog, Paul J ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b MONASH UNIVERSITY   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d Bernard O'Brien Institute of Microsurgery   (Australia)

Author keywords

Constitutive activation; gp130; Neuroendocrine (NE); Prostate cancer

Indexed keywords

ANDROGEN; CHROMOGRANIN A; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; CELL VACUOLE; CONTROLLED STUDY; DENSE CORE VESICLE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NEURITE; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN PROTEIN INTERACTION; SCID MOUSE; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOGRANIN A; CHROMOGRANINS; CYTOKINE RECEPTOR GP130; HISTOCYTOCHEMISTRY; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MICE, SCID; MICROSCOPY, ELECTRON, TRANSMISSION; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; SECRETORY VESICLES;

EID: 12344314055     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20143     Document Type: Article

References (26)

1. ACS. Cancer facts and figures. American cancer society, Inc., 2003.
2. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 1998;12(1):20-25.
3. Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF. Serum chromogranin-A in advanced prostate cancer. BJU Int 2001;88(7):790-796.
4. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl 1998;8:43-51.
5. Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 2000;196(5):277-284.
6. Noordzij MA, van Weerden WM, de Ridder CM, et al. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1996;149(3):859-871.
7. Gkonos P, Krongrad A, Roos B. Neuroendocrine peptides in the prostate. Urol Res 1995;23:81.
8. Deeble P, Cox M, Wu M, Parsons SJ. Neuroendocrine cells and paracrine signaling in prostate cancer progression. Recent Res Devel Endocrinol 2001;2:357-374.
9. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001;21(24):8471-8482.
10. Hoosein NM. Neuroendocrine and immune mediators in prostate cancer progression. Front Biosci 1998;3:D1274-D1279.
11. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999;59(15):3821-3830.
12. Burchardt T, Burchardt M, Chen M-W, Cao Y, De La Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162:1800-1805.
13. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91(12):5330-5334.
14. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000;42(3):186-195.
15. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277(9):7076-7085.
16. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38(3):199-207.
17. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159(6):2159-2165.
18. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998;393(6680):83-85.
19. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001;7(6):1773-1781.
20. Hannemann J, Hara T, Kawai M, Miyajima A, Ostertag W, Stocking A. Sequential mutations in the interleukin-3(IL-3)/Granulocyte-macrophage colony stimulating factor/IL-5 receptor beta-subunit genes are necessary for the complete coversion to growth autonomy mediates by a truncated beta C subunit. Mol Cell Biol 1995;15(5):2402-2412.
21. Militi S, Riccioni R, Parolini I, Sposi NM, Samoggia P, Pelosi E, Testa U, Peschle C. Expression of interleukin 3 and granulocytemacrophage colony-stimulating factor receptor common chain betac, betaIT in normal haematppoiesis: Lineage specificity and proliferation-independent induction. Br J Haematol 2000;111(2):441-451.
22. Hammacher A, Richardson RT, Layton JE, Smith DK, Angus LJ, Hilton DJ, Nicola NA, Wijdenes J, Simpson RJ. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor. J Biol Chem 1998;273(35):22701-22707.
23. Lewis PR, Knight Elsevier DP. Cytochemical staining methods for Electron Microscopy Series: Practical methods in electron microscopy, Vol. 14. Editor: Audrey M. Glauert. 1992:321p.
24. Johns T, Mackay I, Callister K, Hertzog P, Devenish R, Linnane A. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: Higher efficacy of Interferon beta. J Nat Cancer Inst 1992;84:1185-1190.
25. Copenhaver WM, Kelly DE, Wood RL. Bailey's textbook of histology, 17th edn. Baltimore, USA: Williams & Wilkins Company; 1979.
26. Palmer J, Hertzog PJ, Hammacher A. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells. Int J Biochem Cell Biol 2004; In Press.